Simon Lord Selected Research

Simon Lord Research Topics

Disease

11	Neoplasms (Cancer) 11/2022 - 08/2011
5	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2010
3	Hypoxia (Hypoxemia) 01/2019 - 08/2011
2	Disease Progression 01/2021 - 01/2019
1	Cardiotoxicity 01/2022
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 01/2022
1	Heart Failure 01/2022
1	Inflammation (Inflammations) 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Left Ventricular Dysfunction 01/2022
1	Hypersensitivity (Allergy) 01/2021
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2021
1	Frailty 01/2021
1	Skin Neoplasms (Skin Cancer) 01/2021
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2015
1	Carcinogenesis 10/2014

Drug/Important Bio-Agent (IBA)

2	Adenosine Triphosphate (ATP)IBA 11/2022 - 10/2014
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2011
2	Pharmaceutical PreparationsIBA 10/2021 - 01/2016
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 08/2016
2	Hormones (Hormone)IBA 01/2019 - 01/2019
1	candesartanIBA 01/2022
1	Carvedilol (Coreg)FDA LinkGeneric 01/2022
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2022
1	TroponinIBA 01/2022
1	AnthracyclinesIBA 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022
1	Troponin IIBA 01/2022
1	Gadolinium DTPA (Magnevist)FDA Link 01/2022
1	Designed Ankyrin Repeat ProteinsIBA 10/2021
1	MP0250IBA 10/2021
1	Capecitabine (Xeloda)FDA Link 01/2021
1	berzosertibIBA 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021
1	VX (EDIM)IBA 01/2021
1	PlatinumIBA 01/2021
1	Protein Kinases (Protein Kinase)IBA 01/2021
1	3' Untranslated Regions (3' UTR)IBA 01/2021
1	P-2 (P 2)IBA 01/2021
1	Glutamine (L-Glutamine)FDA Link 01/2019
1	Estrogen ReceptorsIBA 01/2019
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2019
1	Fulvestrant (Faslodex)FDA Link 01/2019
1	Ado-Trastuzumab EmtansineIBA 01/2019
1	Amino Acids FDA Link 01/2019
1	trastuzumab duocarmazineIBA 01/2019
1	Bevacizumab (Avastin)FDA Link 08/2016
1	Oxygen (Dioxygen)IBA 01/2016
1	fibrin fragment D (D-dimer)IBA 01/2015
1	Imatinib Mesylate (Gleevec)FDA Link 01/2015
1	Perilipin-2IBA 10/2014
1	Fatty Acids (Saturated Fatty Acids)IBA 10/2014
1	GlycogenIBA 10/2014
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2014
1	LipidsIBA 10/2014
1	MicroRNAs (MicroRNA)IBA 08/2011

Therapy/Procedure

8	Therapeutics 11/2022 - 12/2010
3	Drug Therapy (Chemotherapy) 01/2022 - 01/2021
1	Intravenous Administration 01/2022
1	Combination Drug Therapy (Combination Chemotherapy) 01/2021
1	Neoadjuvant Therapy 08/2016